Grifols, S.A. / Novartis Diagnostics (blood transfusion unit)

Transfusion Medicine / Blood & Plasma Donor Screening

$1.0B Acquired unit projected ~$1.0B annual revenue post-close

Disease Overview

Donor screening uses molecular and serological assays to detect HIV, HCV, HBV, WNV, and other transfusion-transmissible pathogens before blood/plasma units enter the supply chain. Nucleic acid testing (NAT) shrinks the infectious-window period versus antibody assays and is mandated for major blood services in developed markets.

Competitive Landscape

The 2013 transfusion-screening market was effectively a duopoly. Grifols/Novartis-Hologic (the Procleix NAT franchise on Tigris and Panther platforms) competed primarily with Roche Diagnostics' cobas s 201/s 401 NAT systems, with serology supplied by Abbott (PRISM) and Ortho Clinical Diagnostics. The Procleix platform — built on transcription-mediated amplification (TMA) chemistry from Gen-Probe/Hologic — covered over 80% of the US blood supply at deal time. Grifols's purchase of Novartis's commercial rights converted it from a peripheral diagnostics player (~4% of company revenue) into the global leader in transfusion screening (~20%+ of revenue, ~$1B turnover), vertically integrating NAT donor screening with its core plasma-derived therapies and donor-center operations. The deal mattered because it locked Grifols into a sticky, recurring-reagent franchise with high regulatory barriers to entry and set up the 2017 buyout of Hologic's remaining stake that gave Grifols full ownership.